Planmed Clarity 3D – new DBT system receives CE mark and wins Red Dot Design Award
The Planmed Clarity™ 3D digital breast tomosynthesis system and the Planmed Clarity™ 2D full field digital mammography system have received the CE mark and are now available for sale in the EU and other countries where the CE mark applies. The systems have also won the prestigious Red Dot Design Award.
Digital breast tomosynthesis produces a 3D volume of the breast and resolves the challenge of overlapping tissue structures. This results in enhanced diagnostics, especially for patients with denser breast tissue. Planmed’s patented new tomosynthesis method significantly improves image accuracy and allows even the smallest details to be captured with great precision.
“We are very excited about the CE clearance, as it permits us to launch a new and improved method to combat breast cancer. The Red Dot Design Award is a further testament to our dedication and hard work”, states Jan Moed, Managing Director of Planmed.
In addition to the Planmed Clarity 3D digital breast tomosynthesis system, the new product family also includes the Planmed Clarity 2D digital mammography system, which can be easily upgraded to digital breast tomosynthesis at any time. Both systems allow imaging with a low effective patient dose and feature a durable digital detector for mobile screenings, as well as the new Planmed Clarity™ Flow touch control with dual touchscreens.
”We are convinced that both systems will be well accepted. The Red Dot jury especially valued their eye-catching and functional design, which also enhances ergonomics. The adaptive touch control of the systems will provide an unforeseen user experience”, Moed continues.
The Planmed Clarity systems provide outstanding image quality and enable a fast and reliable workflow in all situations – from screenings to diagnostic imaging and biopsy procedures. A positive patient experience is also one of Planmed’s guiding design principles. ”We can reduce patient anxiety with the design of the systems and consequently encourage more women to participate in breast cancer screenings”, Moed concludes.
For more information, please contact:
Jan Moed
Managing Director, Planmed Oy
Tel. 00 358 20 779 5387
jan.moed@planmed.com
Planmed Oy and Planmeca Group
Planmed Oy develops, manufactures and markets advanced imaging equipment and accessories for mammography and orthopedic imaging. Planmed's extensive mammography product range covers digital and analog units and digital breast tomosynthesis (DBT) systems, stereotactic biopsy devices, and breast positioning systems for an early detection of breast cancer. Within orthopedic 3D imaging Planmed offers low dose extremity CT imaging for quicker, easier and more accurate diagnosis at the point-of-care. Strongly committed to R&D and design, Planmed Oy exports more than 98% of its production to over 70 countries worldwide. Planmed Oy was established in 1989 and the company’s headquarters are located in Helsinki, Finland.
Planmed Oy is part of the Finland-based Planmeca Group that manufactures and markets state-of-the-art products for the medical and dental fields. The Group's turnover in 2014 was approximately EUR 740 million and it employs nearly 2,700 people worldwide.
www.planmed.com
